A significant fraction of pharma and biotech pipelines is comprised of poorly soluble and, hence, poorly bioavailable compounds. Amorphous solid dispersions (ASDs) are a proven technology that have been commercialized in over twenty products. Key to progressing ASDs is the use of rapid, bulk sparing methods to characterize ASD performance and identify commercially relevant formulations early and avoid re-formulation later in the project lifecycle. This talk will focus on identification of methods for predicting ASD performance and case studies for poorly soluble molecules.
David K. Lyon, Senior Fellow, Global R&D, Lonza Pharma & Biotech